Halia Therapeutics Inc. has reported the development of tyrosine-protein kinase receptor TYRO3 inhibitors potentially useful for the treatment of glioma.
Cullgen (Shanghai) Inc. has patented proteolysis targeting chimera (PROTAC) compounds comprising a DDB1 binding moiety covalently bonded to a target protein binding moiety through a linker. They are reported to be useful for the treatment of cancer.
Compounds reported to be useful for the treatment of myotonic 1, myotonic 2 and muscular dystrophy have been described in a City University of New York patent.
Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. and Medshine Discovery Inc. have jointly patented pyrimidine tricyclic derivative soluble guanylate cyclase (sGC) activators. They are reported to be useful for the treatment of heart failure and hypertension.
Biosplice Therapeutics Inc. has prepared and tested pyrrolo[2,1-F][1,2,4]triazines derivatives acting as dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and reported to be useful for the treatment of cancer, diabetes and neurological disorders.
Research at Vasa Therapeutics Sp zoo has led to the identification of diazabicyclooctane derivatives acting as matrix metalloproteinase (MMP) inhibitors and thus reported to be useful for the treatment of heart failure.
New optically active benzodiazepines have been reported in a recent Kyonggi University patent as potentially useful for the treatment of diabetic neuropathy.
Tango Therapeutics Inc. has patented histone-lysine N-methyltransferase EHMT1 (H3-K9-HMTase 5; GLP) and/or EHMT2 inhibitors reported to be useful for the treatment of cancer, sickle cell disease and β-thalassemia.
RSS